Cancer Dx Firm Pacific Edge Achieves CLIA Registration to Offer Bladder Cancer Test in US | GenomeWeb

NEW YORK (GenomeWeb News) – New Zealand cancer diagnostics company Pacific Edge said today its US Laboratory has achieved registration under the CLIA regulatory process, setting the stage for it to offer its bladder cancer test in the US.

CLIA registration means that Pacific Edge's laboratory in Hershey, Penn., will be able to operate and process urine samples from patients in the US for its laboratory-developed test called Cxbladder. The non-invasive, urine-based test uses molecular signatures to identify the presence of bladder cancer tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."